Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBITDA: 2013-2022

Historic EBITDA for Cellectis (CLLS) over the last 10 years, with Dec 2022 value amounting to -$89.7 million.

  • Cellectis' EBITDA rose 24.43% to -$20.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$73.4 million, marking a year-over-year increase of 32.34%. This contributed to the annual value of -$89.7 million for FY2022, which is 13.35% up from last year.
  • Per Cellectis' latest filing, its EBITDA stood at -$89.7 million for FY2022, which was up 13.35% from -$103.5 million recorded in FY2021.
  • Cellectis' 5-year EBITDA high stood at -$42.3 million for FY2020, and its period low was -$123.6 million during FY2019.
  • Its 3-year average for EBITDA is -$78.5 million, with a median of -$89.7 million in 2022.
  • As far as peak fluctuations go, Cellectis' EBITDA surged by 65.75% in 2020, and later plummeted by 144.57% in 2021.
  • Cellectis' EBITDA (Yearly) stood at -$105.1 million in 2018, then dropped by 17.57% to -$123.6 million in 2019, then soared by 65.75% to -$42.3 million in 2020, then tumbled by 144.57% to -$103.5 million in 2021, then climbed by 13.35% to -$89.7 million in 2022.